Sinovac Biotech (SVA) AI Stock Analysis

137 Followers

Sinovac Biotech

(NASDAQ:SVA)

Select Model

Rating:49Neutral

Price Target:$6.50▲(0.46% Upside)

Action:initiatedcoverage

Date:10/17/26

The score is held down primarily by weak financial performance—particularly the sharp deterioration to deeply negative operating and free cash flow in 2025, alongside ongoing net losses. Technicals are largely neutral with flat moving averages and a flat MACD, offering limited support. Valuation is also constrained by a negative P/E, which reflects loss-making operations rather than demonstrably attractive earnings value.

Positive Factors

International Revenue ExpansionRapid overseas growth is diversifying Sinovac beyond its domestic base and improving the revenue mix. Expansion across international markets can create a broader commercial platform for existing and newly approved vaccines, supporting more durable growth over the next several quarters.

Negative Factors

Persistent Losses and Cash BurnDeeply negative operating and free cash flow materially weaken Sinovac’s ability to fund operations and development internally. Continued cash burn, alongside recurring net losses, could force greater reliance on existing balance-sheet resources and constrain investment flexibility.

Sinovac Biotech (SVA) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $460.27M
Dividend Yield: ―
Average Volume (3M): 8,227
Price to Earnings (P/E): -7.8
Beta (1Y): ―
Revenue Growth: 8.78%
EPS Growth: -227.47%
Country: US
Employees: 1,959
Sector: General
Sector Strength: 55
Industry: Medical - Pharmaceuticals

Sinovac Biotech Business Overview & Revenue Model

Company Description

Sinovac Biotech Ltd. is a biopharmaceutical firm primarily dedicated to the discovery, research, manufacturing, and sales of vaccines aimed at combating infectious human diseases across the People's Republic of China. Its extensive product range enco...

Sinovac Biotech Financial Statement Overview

Summary

Financial performance is pressured by weak profitability and cash generation. The income statement shows revenue stabilizing with solid gross margin (~67.9% in 2025), but 2025 still recorded a sizable net loss (~$59.7M). The balance sheet is conservatively levered (debt-to-equity ~0.11), yet equity has declined and returns are slightly negative. The biggest drag is cash flow: 2025 operating cash flow (~-$510.5M) and free cash flow (~-$559.4M) were deeply negative, indicating significant cash burn.

Income Statement

27Negative

Balance Sheet

64Positive

Cash Flow

22Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	448.27M	386.01M	361.37M	448.27M	1.49B	19.37B
Gross Profit	259.86M	261.98M	220.69M	266.75M	808.30M	18.30B
EBITDA	-6.03M	-187.66M	-369.67M	-6.03M	183.10M	17.65B
Net Income	-99.92M	-59.68M	90.91M	-99.92M	113.87M	8.47B
Balance Sheet
Total Assets	13.66B	8.64B	12.34B	13.66B	14.11B	16.75B
Cash, Cash Equivalents and Short-Term Investments	11.22B	6.64B	9.95B	11.22B	11.31B	13.42B
Total Debt	298.98M	506.97M	391.32M	298.98M	74.67M	144.91M
Total Liabilities	1.64B	2.23B	2.04B	1.64B	1.40B	2.87B
Stockholders Equity	8.71B	4.44B	8.26B	8.71B	8.92B	9.33B
Cash Flow
Free Cash Flow	-39.67M	-559.40M	-152.85M	-41.69M	-1.17B	14.63B
Operating Cash Flow	106.02M	-510.49M	-56.89M	104.00M	-770.75M	15.35B
Investing Cash Flow	-2.93B	4.39B	456.36M	-2.93B	-5.76B	-3.02B
Financing Cash Flow	-76.06M	-3.43B	-823.95M	-76.06M	-241.40M	-1.90B

Sinovac Biotech Risk Analysis

Sinovac Biotech disclosed 71 risk factors in its most recent earnings report. Sinovac Biotech reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks

1.Our operating results have fluctuated significantly, and we may incur losses in the future.Q4, 2025

2.We are subject to credit, collection and accounts receivable risks, and delays in collection or bad debts could adversely affect our cash flows and results of operations.Q4, 2025

3.Significant disruptions of IT systems, breaches of information security and cyber threats could adversely affect our business.Q4, 2025

Sinovac Biotech Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

SVA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KNSA	80Outperform	$7.47B	66.97	17.27%	―	58.19%	192.34%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
SCYX	53Neutral	$35.04M	-2.92	-18.65%	―	543.96%	72.49%
SVA	49Neutral	$460.27M	-7.79	-0.94%	―	8.78%	-227.47%
NSRX	28Underperform	$34.96M	-2.83	-158.83%	―	―	―

* General Sector Average

Performance Comparison

SVA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SVA	Sinovac Biotech	6.47	0.00	0.00%
SCYX	SCYNEXIS Inc	3.42	-1.30	-27.65%
KNSA	Kiniksa Pharmaceuticals Ltd. Class A	95.76	55.47	137.68%
NSRX	Nasus Pharma Ltd.	2.91	-4.99	-63.16%
CUVL	Clinuvel Pharmaceuticals Limited Sponsored ADR	5.09	-2.12	-29.39%
ETRA	Electra Therapeutics Inc.	9.45	-3.80	-28.68%

Sinovac Biotech Corporate Events

Sinovac Posts Wider H1 2026 Loss as Overseas Vaccine Sales and New Approvals Reshape Growth Mix

Aug 17, 2026

Sinovac Biotech reported unaudited results for the six months ended June 30, 2026, showing sales up 12.9% year on year to $147.1 million, driven by an 82.3% surge in overseas revenue, which reached $66.5 million and accounted for 45.2% of total sales...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 17, 2026

Sinovac Biotech AI Stock Analysis